Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Journal of Medicinal Chemistry|August 24, 2013
Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myelomaBrent D G Page, Danielle C Croucher, Zhi Hua Li, et al.
Nature Communications|May 12, 2017
Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspiratesOlena Kis, Rayan Kaedbey, Signy Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in miceXiaohua Xin, Tinya J Abrams, Paul W Hollenbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemiaChristine I Chen, P Leif Bergsagel, Harminder Paul, et al.
The Lancet. Oncology|November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trialSuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
European Journal of Haematology|April 12, 2011
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patientsMaurizio Zangari, Monette Aujay, Fenghuang Zhan, et al.
Blood|December 6, 2017
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemiaChristine Chen, David Siegel, Martin Gutierrez, et al.
Cancer|July 27, 2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
Blood|September 19, 2007
A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitinXinliang Mao, A Keith Stewart, Rose Hurren, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 14, 2025
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in CanadaHira S Mian, Alissa Visram, Steven Chun-Min Shih, et al.
Pageof 11